SHANGHAI FUDAN H YC-,10
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more
SHANGHAI FUDAN H YC-,10 (FDY) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SHANGHAI FUDAN H YC-,10 (FDY) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SHANGHAI FUDAN H YC-,10 - Net Assets Trend (None–None)
This chart illustrates how SHANGHAI FUDAN H YC-,10's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SHANGHAI FUDAN H YC-,10 (None–None)
The table below shows the annual net assets of SHANGHAI FUDAN H YC-,10 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SHANGHAI FUDAN H YC-,10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SHANGHAI FUDAN H YC-,10 Competitors by Market Cap
The table below lists competitors of SHANGHAI FUDAN H YC-,10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Information Services Group Inc
NASDAQ:III
|
$141.00 Million |
|
Azul SA
NYSE:AZUL
|
$141.03 Million |
|
Malaysia Smelting Corporation Bhd
KLSE:5916
|
$141.04 Million |
|
Caltagirone SpA
STU:QCG
|
$141.05 Million |
|
SPARX Group Co. Ltd
PINK:SRXXF
|
$140.83 Million |
|
Kyobo Securiti
KO:030610
|
$140.83 Million |
|
Jiangsu Smartwin Electronics Technology Co.Ltd.
SHE:301106
|
$140.83 Million |
|
Planet Technology
TWO:6263
|
$140.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SHANGHAI FUDAN H YC-,10's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SHANGHAI FUDAN H YC-,10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SHANGHAI FUDAN H YC-,10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SHANGHAI FUDAN H YC-,10's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SHANGHAI FUDAN H YC-,10 (FDY) | €- | N/A | N/A | $140.98 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |